Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
Pérez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, Fornander T, Skoog L, Stål O.
Pérez-Tenorio G, et al. Among authors: fornander t.
Breast Cancer Res Treat. 2011 Aug;128(3):713-23. doi: 10.1007/s10549-010-1058-x. Epub 2010 Oct 16.
Breast Cancer Res Treat. 2011.
PMID: 20953835